MONOPAR THERAPEUTICS INC.

Analyst Reco. Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Market Closed - Nasdaq Other stock markets 02:00:00 02/05/2024 am IST			5-day change	1st Jan Change
0.65 ^USD	-1.53%		-1.07%	+91.06%

16/04	Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	MT
16/04	Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JonesTrading Upgrades Monopar Therapeutics to Buy From Hold, Price Target is $2	11/04	MT
JonesTrading Downgrades Monopar Therapeutics to Hold From Buy	10/23/10	MT
HC Wainwright Adjusts Monopar Therapeutics' Price Target to $2 From $6, Keeps Buy Rating	15/23/15	MT
Maxim Group Downgrades Monopar Therapeutics to Hold From Buy	29/23/29	MT
Roth MKM Adjusts Price Target on Monopar Therapeutics to $3 From $18, Maintains Buy Rating	28/23/28	MT
EF Hutton Adjusts Price Target on Monopar Therapeutics to $17 From $24, Maintains Buy Rating	28/23/28	MT
Roth Capital Reinstates Monopar Therapeutics at Buy With $18 Price Target	09/22/09	MT
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High	05/22/05	MT
HC Wainwright Adjusts Monopar Therapeutics' Price Target to $6 From $9, Maintains Buy Rating	16/22/16	MT
HC Wainwright Starts Monopar Therapeutics at Buy With $9 Price Target	01/21/01	MT
MONOPAR THERAPEUTICS : Roth Capital Starts Monopar Therapeutics at Buy With $49 Price Target	28/21/28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer